AACR 2021: Novel Engineered B-NDG B2M KO Mice Plus Shows Delayed GvHD response and Favorable GvL Immune Profiling After hPBMC Engraftment

AACR 2021: Novel Engineered B-NDG B2M KO Mice Plus Shows Delayed GvHD response and Favorable GvL Immune Profiling After hPBMC Engraftment

• B-NDG B2M KO mice plus exhibit immunodeficient phenotypes, in which T, B, and NK cells are defective with some histopathological changes in lymphoid organs.
• B-NDG B2M KO mice plus have significantly delayed and minimized GvHD and prolonged animal survival after human PBMC engraftment.
• Human CD45+ cells are present with increased CD8/Treg ratio in hPBMC engrafted B-NDG B2M KO mice plus, suggesting that the reduced GvHD is due to efficient B2M KO in the mice, and not due to immune tolerance development.
• B-NDG B2M KO mice plus is a validated mouse strain for efficacy studies in hPBMC reconstituted xenograft tumor models.